



## Prostate Cancer: Molecular Imaging and Radionuclide Therapy

Guest Editor:

**Dr. Sara Harsini**

BC Cancer Research Institute,  
Vancouver, BC, Canada

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### Message from the Guest Editor

Dear Colleagues,

I am thrilled to announce the upcoming release of a Special Issue in *Biomedicines*, entitled "Prostate Cancer: Molecular Imaging and Radionuclide Therapy." This collection of articles will feature contributions from leading experts in the field of positron emission tomography/computed tomography (PET/CT) and radionuclide therapies for prostate cancer. The rapidly evolving field of theranostics, which combines diagnostic and therapeutic radiopharmaceutical agents, is revolutionizing prostate cancer imaging and paving the way for improved treatment strategies. This Special Issue aims to highlight recent advancements in molecular imaging and radionuclide therapy that have already impacted the management of prostate cancer and those that have the potential to shape the diagnostic and treatment paths of the disease in the near future.

Dr. Sara Harsini

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)